
Now at #UromigosLive Nashville 🎸 Sequencing of therapy across the continuum of advanced #prostatecancer 🔄 With @brian_rini @AttardLab @neerajaiims @TDorffOnc Evan Yu ARPI, PARPi, RLT, chemo… 💊how do we order them? @Uromigos
✓Genito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University

Now at #UromigosLive Nashville 🎸 Sequencing of therapy across the continuum of advanced #prostatecancer 🔄 With @brian_rini @AttardLab @neerajaiims @TDorffOnc Evan Yu ARPI, PARPi, RLT, chemo… 💊how do we order them? @Uromigos

Now @shilpaonc @ClevelandClinic v @CMercinelli @SanRaffaeleMI debating #RIPTAC v #BiTE in #prostatecancer. Good points on both sides at @Uromigos #UromigosLive @OncoAlert @brian_rini @tompowles1

🇮🇹⚔️🇮🇳 What a match at #Uromigos World Cup! Great debate with @shilpaonc on the newest drugs in #Prostatecancer 🔥 #UromigosLive @Uromigos @LosUromigos @brian_rini @tompowles1

RIPTACs vs T-cell engagers at The Uromigos World Cup👉exciting data👇. Two very promising approaches in #prostatecancer, and great news for our patients #UromigosLive @Uromigos @OncoAlert @brian_rini @tompowles1 @shilpaonc @CMercinelli Congrats to both debaters!!


European teams united in Nashville 🇪🇺 #UromigosLive @Uromigos @OncoAlert @oncodaily

The FIFA World Cup may be over, but the REAL @Uromigos World Cup is heating up! ⚽🏆🔥 The #UromigosLive World Cup brings together 14 teams around the 🌍 international rivalries, fierce competition, brilliant science, and plenty of laughs! 🌍🏆 @brian_rini @tompowles1 @uromigosjapan @LosUromigos

The Azzurri Team has landed in Nashville 🇮🇹💪 Forza Italia!! #UromigosLive @Uromigos @tompowles1 @giannatempopatr @OncoAlert @oncodaily


Terrific video - having been to @AndreaNecchi's brilliant meeting for several years now, it's hard to compete with #Milan. Bravo @giannatempopatr & @CMercinelli for a great tour of the city & some good facts ahead of #UromigosLive26. @brian_rini @tompowles1

FOR-ZA! FOR-ZA! 🇮🇹 Italy 🇮🇹 Italy 🇮🇹 @giannatempopatr @CMercinelli 🏆 🏆 🏆 #UromigosLive 13th 14th November Livestream bladder cancer session 13th 2pm EST Tomorrow 🇯🇵 🇯🇵 🇯🇵 @OncoAlert @montypal @DrChoueiri @neerajaiims @shilpaonc

Bladder preservation after neoadjuvant/perioperative therapy in 🇮🇹 MIBC pts who declined RC and underwent reTURBT (n=54) 📌Negative imaging, biopsy & cytology 🔹19% recurred; 13% developed distant recurrence 🔹 ypT0Nx at reTURBT → 24-mo EFS 88%; MFS & OS >95%, comparable with ypT0N0 after RC 🔹 Residual disease at reTURBT → substantially worse vs non-pCR after RC: 24-mo EFS 19% vs 68%; OS 50% vs 83% 🔹 20% required delayed RC or chemoRT 🔹 Baseline cT3–4 disease also associated with poorer outcomes 🔑 Pathologic clearance at reTURBT may identify a highly selected group for bladder preservation; residual disease was associated with markedly inferior outcomes vs RC. @urotoday #ESMO26

Outcomes of Patients with #MIBC Who Declined Radical Cystectomy in Perioperative Therapy Trials Conducted at San Raffaele Comprehensive Cancer Center. Presented by @CMercinelli @SanRaffaeleMI. #ESMO26 written coverage by @rksayyid @UAUrology > bit.ly/4Bxa9KE #BladderCancer #GUOnc @myESMO

Huge congrats @AndreaNecchi & team on this yet another novel trial. You are always pushing the envelope in bladder cancer! @CMercinelli @BrigidaMaiorano @giannatempopatr @UroDocAsh @montypal @PGrivasMDPhD @SpiessPhilippe @IBCG_BladderCA

This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR Outcomes of pts with MIBC who decline RC in perioperative setting: Take-home message: 1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT 2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al. Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open esmoopen.com/article/S2059-7…

With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting. 33% CR rates vs 8% Nivo+placebo All pCR pts still event-free (median FUP 15.7m) Only 1 relapse event in major responders in N+V arm (pTa relapse) 4/5 pCR skipped RC in N+V arm. Safety was quite good. Pre-existing CD8+ infiltration associated with N+V Response. It was an illuminating academic-industry collaboration for me. Results simultaneously released today in @NatureMedicine @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR nature.com/articles/s41591-0…